
- /
- Supported exchanges
- / F
- / LIA.F
LivaNova PLC (LIA F) stock market data APIs
LivaNova PLC Financial Data Overview
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get LivaNova PLC data using free add-ons & libraries
Get LivaNova PLC Fundamental Data
LivaNova PLC Fundamental data includes:
- Net Revenue: 1 275 M
- EBITDA: 225 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LivaNova PLC News

Are Options Traders Betting on a Big Move in LivaNova Stock?
Investors in LivaNova PLC LIVN need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 18, 2025 $32.50 Put had some of the highest implied volatil...


CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LONDON, June 05, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market...

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-mon...

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
Final critical papers on RECOVER clinical study data accepted, supporting the Company’s submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.